Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 2;25(1):38. doi: 10.3892/mmr.2021.12554

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Zhu et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 4. — Prediction and analysis of potential target genes of miR-136-5p. (A) Target genes of miR-136-5p were predicted using bioinformatics tools (starBase, miRWalk, TargetScan, ONCOMIR and miRDB). (B) Expression profile of seven target genes of miR-136-5p was analyzed using the UALCAN database. (C) Increased B3GNT5 expression was detected in LIHC in the GEPIA database. (D) OS and DFS of patients with liver cancer with different expression profiles of B3GNT5. GSCA database was used to study the SNV, copy number alteration and methylation levels of target genes. (E) SNV percentage of target genes in liver cancer. (F) Missense mutation of B3GNT5 in liver cancer. (G) CNV types of B3GNT5 in liver cancer. (H) B3GNT5 methylation levels across TCGA cancer types. (I) Methylation difference of target genes in liver cancer. (J) Correlation between methylation and mRNA expression levels of target genes of miR-136-5p. (K) Negative correlation between B3GNT5 methylation level and mRNA expression. *P<0.05. miR, microRNA; GEPIA, Gene Expression Profiling Interactive Analysis; OS, overall survival; DFS, disease-free survival; SNV, single nucleotide variation; CNV, copy number variation; TCGA, The Cancer Genome Atlas; WT, wild-type; MUT, mutant; FDR, false discovery rate; LIHC, liver hepatocellular carcinoma.